Belgium-based life sciences company VolitionRx Ltd (NYSEMKT:VNRX) has acquired a new research and development (R&D) facility in the Wallonia region of Belgium for €1.2mln.
The company expects to move into the new facility, in the Crealys Science Park in Les Isnes, in March of next year.
The company was running out of space at its current facilities, so the shift to new premises will give the company the space to carry out clinical trials with additional lab machines and to fit in a few more scientists.
“We are looking forward to moving into our new R&D facility as we are exceeding maximum capacity at our current facilities. We believe that this exciting upgrade will allow us to accelerate our clinical trials and expedite the commercialization of our products” said Dr Gaetan Michel, chief executive officer of Belgian Volition.
The company also revealed that Dr Philippe Willemsen has been lured over from Promethera Biosciences to become chief operating officer for VolitionRx’s wholly-owned subsidiary, Belgian Volition SPRL.
“He brings with him a wealth of experience and joins us at an exciting time as we prepare to launch our first Nu.QTM test. His appointment to manage operations in Belgium will allow me to focus on my role as global product manager for the Nu.QTM Colorectal Cancer Screening Triage Test (blood test), for which we expect to receive CE marking later this year,” said Dr Michel.
Story by ProactiveInvestors